Antiphospholipid antibodies and antiphospholipid syndrome in patients with malignancies: features, incidence, identification, and treatment

Seminars in Thrombosis and Hemostasis
Wolfgang Miesbach

Abstract

Thrombotic events associated with antiphospholipid (aPL) antibodies can be the first manifestation of malignancy. The pathologic significance of aPL antibodies in patients with malignancies, however, is still unclear. It remains an unresolved issue as to whether the presence of aPL antibodies may be considered as an "epiphenomenon" of the malignancy itself or whether it contributes directly to the development of thrombosis in these patients. In particular, solid tumors may be associated with the development of aPL antibodies, enhancing the thrombophilic risk in these patients. In general, routine anticoagulant prophylaxis with low-molecular-weight heparin in cancer patients with positive aPL antibodies is strongly indicated.

Citations

Jul 17, 2009·Current Opinion in Hematology·Suman L Sood
Nov 19, 2011·Journal of Veterinary Internal Medicine·L N NielsenA T Kristensen
Feb 1, 2011·Clinical Chemistry and Laboratory Medicine : CCLM·Emmanuel J Favaloro, Richard C W Wong
Aug 18, 2012·Asia-Pacific Journal of Clinical Oncology·Metin OzkanOzlem Er
Apr 10, 2015·Current Rheumatology Reports·Cassyanne L AguiarBarry L Myones
Feb 21, 2014·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Grace Chang, James J Yeh
Dec 14, 2018·Frontiers in Pediatrics·Chris Wincup, Yiannis Ioannou
May 1, 2010·Auto- Immunity Highlights·Emmanuel J Favaloro, Richard C W Wong

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.